Skip to main content

Month: May 2022

Vericel Reports First Quarter 2022 Financial Results

First Quarter Total Net Revenue of $36.1 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the first quarter ended March 31, 2022. First Quarter 2022 Financial HighlightsTotal net revenue of $36.1 million, compared to $34.6 million in the first quarter of 2021 MACI® net revenue of $26.0 million, Epicel® net revenue of $9.9 million, and NexoBrid® revenue of $0.2 million related to the U.S. Biomedical Advanced Research and Development Authority (“BARDA”) procurement for emergency response preparedness Gross margin of 65%, compared to 66% in the first quarter of 2021 Net loss of $7.1 million, or $0.15...

Continue reading

Trailbreaker Resources Acquires the Connector Gold Property, Adjacent to the Past-Producing Brenda Mine

VANCOUVER, British Columbia, May 04, 2022 (GLOBE NEWSWIRE) — Trailbreaker Resources Ltd. (TBK.V) (“Trailbreaker” or “the Company”) is pleased to announce the acquisition of the Connector Gold property in the Merritt area of British Columbia (BC). The newly-staked claims are located just 500 metres north of the past-producing Brenda Cu-Mo (copper-molybdenum) mine. Highlights of the new Connector Gold propertyLocated 40 km north of Kelowna and 55 km southeast of Merritt, BC, and straddles Highway 97C (the Okanagan Connector) Excellent road accessibility via numerous well maintained forest service roads that extend from the highway 100%-owned by Trailbreaker Resources with no underlying payments or royalties Covers 1,894 hectares of ground just 500 m north of the past-producing Brenda Cu-Mo mine 15 km northeast of the producing...

Continue reading

With 17.2% CAGR, Orthodontics Market Size worth USD 16.36 Billion by 2026

Key Prominent Players Covered in the Orthodontics Market Research Report Are Institut Straumann AG (Basel, Switzerland) , Dentsply Sirona (Pennsylvania, U.S.) , 3M (Minnesota, U.S.) , Ormco Corporation (Brea, U.S.) , DB Orthodontics (Silsden, U.K.) , Henry Schein, Inc. (New York U.S.) , Align Technology, Inc. (San Jose, U.S.) , AMERICAN ORTHODONTICS (Wisconsin, U.S.) , Great Lakes Dental Technologies (Tonawanda, U.S.) Pune, India, May 04, 2022 (GLOBE NEWSWIRE) — The global orthodontics market size was USD 4.76 billion in 2020. The market is USD 5.38 billion in 2021 and is expected to reach USD 16.36 billion in 2028 at a CAGR of 17.2% in the 2021-2028 period. This information is published by Fortune Business Insights™, in its report, titled, “Orthodontics Market, 2021-2028.” According to our research experts, owing to the several...

Continue reading

United Community Banks, Inc. and Progress Financial Corporation Announce Merger Agreement

Expanding Further into Attractive Southeastern Markets GREENVILLE, S.C. and HUNTSVILLE, Ala., May 04, 2022 (GLOBE NEWSWIRE) — United Community Banks, Inc. (NASDAQGS: UCBI) (“United”) and Progress Financial Corporation (“Progress”) announced today the execution of a definitive merger agreement pursuant to which United will acquire Progress, and its wholly-owned subsidiary, Progress Bank & Trust (the “Merger”), in an all-stock transaction with an aggregate value of approximately $271.5 million, or $23.52 per share of Progress common stock, based on United’s closing stock price of $30.55 as of May 3, 2022. Progress is headquartered in Huntsville, Alabama, and operates 14 offices in high-growth, southeastern markets, including, Huntsville, Birmingham, Daphne and Tuscaloosa in Alabama and the Florida Panhandle. As of March 31,...

Continue reading

Harvard Bioscience Announces First Quarter 2022 Financial Results

  • Revenue up 7% year-over-year despite volatility in China related to COVID-19 and global supply chain headwindsHOLLISTON, Mass., May 04, 2022 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2022. Jim Green, Chairman and CEO, said, “Our revenue was up 7% on strength from North American sales despite the impact of lockdowns in China. Demand for our pre-clinical and cellular/molecular (CMT) products continued to be strong, up 7% and 10%, respectively. Adjusted operating income for Q1 was lower than prior year due primarily to higher material, freight and labor costs associated with ongoing global supply disruptions. We also funded growth investments in R&D and marketing. On a GAAP basis, we recorded an operating loss that...

Continue reading

Oncorus Reports First Quarter 2022 Financial Results and Provides Business Updates

Additional clinical data from ONCR-177 surface lesion monotherapy expansion and combination expansion cohorts expected in second half of 2022 Preclinical data presented for ONCR-021 and ONCR-788 at AACR Annual Meeting supports selectively self-amplifying vRNA/LNP immunotherapy platform; on track to submit IND for ONCR-021 in mid-2023 Multiple tranche debt capital facility with K2 HealthVentures supports completion of GMP-compliant manufacturing facility; cash runway extended into early 2024CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) — Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today reported first quarter 2022 financial results and highlighted recent achievements and developments. “Early 2022 has been focused on clinical and operational...

Continue reading

Conformis Reports First Quarter 2022 Financial Results

BILLERICA, Mass., May 04, 2022 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the first quarter ended March 31, 2022. First Quarter 2022 SummaryTotal revenue of $15.6 million, an increase of 12% year-over-year on a reported basis and 13% on a constant currency basis. Product revenue of $14.9 million, an increase of 9% year-over-year on a reported and constant currency basis. Conformis hip system revenue up 18% year-over-year to $0.8 million. Cash and cash equivalents of $82.7 million as of March 31, 2022. Recently completed the 250th Imprint procedure under the limited market release. New COO, Michael Fillion started April 1, 2022.Executive Commentary – Mark Augusti, President and CEO “We...

Continue reading

ARKO Reports First Quarter 2022 Results

Net Income Increases by $17.0 Million; Adjusted EBITDA Grows 18.4% in Q1 2022 Compared to Q1 2021; Fuel, Merchandise Contribution Grows Beats Consensus with Double-Digit EBITDA Growth Compared to Q1 2021 RICHMOND, Va., May 04, 2022 (GLOBE NEWSWIRE) — ARKO Corp. (Nasdaq: ARKO) (“ARKO” or the “Company”), one of the largest convenience store operators and fuel wholesalers in the United States, today announced financial results for the quarter ended March 31, 2022. First Quarter 2022 Key HighlightsOperating income was $19.3 million for the quarter, an increase of 46% compared to $13.2 million in Q1 2021 Net income was $2.3 million, an increase of almost $17 million compared to a loss of $14.7 million in Q1 2021 Adjusted EBITDA increased 18.4% to $50.1 million for the quarter compared to $42.3 in Q1 2021 Merchandise revenue of $367.0...

Continue reading

Superior Group of Companies, Inc. Reports Operating Results for the First Quarter Ended March 31, 2022

 Compared to the first quarter 2021:Net Sales increased by 21.8% excluding PPE sales The Office Gurus net sales increased 39.7% BAMKO net sales increased 38.3% excluding PPE salesSEMINOLE, Fla., May 04, 2022 (GLOBE NEWSWIRE) — Superior Group of Companies, Inc. (NASDAQ: SGC), today announced its first quarter operating results for 2022. The Company announced that for the first quarter ended March 31, 2022, net sales increased 1.9% to $143.6 million, compared to first quarter 2021 net sales of $140.8 million. Pretax Income was $6.7 million compared to $13.2 million in the first quarter of 2021. Net income was $5.2 million or $0.32 per diluted share compared to $10.5 million, or $0.66 per diluted share for the first quarter of 2021. Michael Benstock, Chief Executive Officer, commented, “Our promotional products segment and our...

Continue reading

Oatly Reports First Quarter 2022 Financial Results

First Quarter Revenue of $166.2 Million Reiterates Fiscal Year 2022 Outlook MALMÖ, Sweden, May 04, 2022 (GLOBE NEWSWIRE) — Oatly Group AB (Nasdaq: OTLY) (“Oatly” or the “Company”), the world’s original and largest oat drink company, today announced financial results for the first quarter ended March 31, 2022. Toni Petersson, Oatly’s CEO, commented, “Given the challenging operating environment, we are pleased with our first quarter revenue results which exceeded our expectations. In March, we saw significant improvements in EMEA and Americas, with record revenue in EMEA and the largest production month ever for the Americas as the manufacturing challenges we experienced at the start of the year due to Omicron began to abate. In Asia, our business was impacted by zero-COVID policy restrictions and subsequent lockdowns, yet what remains...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.